Hai Qiang Mai
Welcome,         Profile    Billing    Logout  
 8 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mai, Hai-qiang
NCT03321539: Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

Active, not recruiting
3
216
RoW
CCRT+GP, Adjuvant GP, CCRT+PF, Adjuvant PF
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/22
12/25
NCT04456322: Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Recruiting
3
326
RoW
RT plus Nimotuzumab, RT plus Cisplatin, Cisplatin
Sun Yat-sen University
Nasopharyngeal Carcinoma
06/23
06/25
NCT03306121: TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma

Active, not recruiting
3
322
RoW
TPF+CCRT, TPF induction chemotherapy, CCRT+ PF, Adjuvant PF
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/23
12/26
NCT05304468: Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Active, not recruiting
3
452
RoW
IMRT, induction chemotherapy, cisplatin concurrent chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
10/26
10/29
NCT06712888: Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Recruiting
3
466
RoW
TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy, GP plus placebo induction therapy
Sun Yat-sen University, First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University Cancer Center, Affiliated Hospital of Guangdong Medical University, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, The University of Hong Kong-Shenzhen Hospital, Hunan Cancer Hospital, The Affiliated Cancer Hosipital of Guizhou Meidical University, Sichuan Cancer Hospital and Research Institute, Fujian Cancer Hospital
Nasopharyngeal Carcinoma (NPC)
01/30
01/32
NCT05979961: Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Recruiting
3
454
RoW
IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy)
Sun Yat-sen University, First Affiliated Hospital of Guangxi Medical University, Zhongshan People's Hospital, Guangdong, China, Wuhan Union Hospital, China, Tongji Hospital, Guangzhou Panyu Central Hospital, Hunan Cancer Hospital, Cancer Hospital of Guizhou Province
Nasopharyngeal Carcinoma
09/26
09/29
NCT03925090: Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Active, not recruiting
2
150
RoW
Cisplatin+Toripalimab, DDP+ JS001, Cisplatin+placebo, DDP
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/21
10/23
NCT05193617: Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Active, not recruiting
2
104
RoW
GP+Penpulimab+Anlotinib, GP+AK105+AL3818, GP+Penpulimab, GP+AK105
Sun Yat-sen University
Nasopharyngeal Carcinoma
01/25
01/27
NCT06301165: TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma

Recruiting
2
162
RoW
TPC induction chemotherapy, GP induction chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/24
12/28
NCT04833257: Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC

Recruiting
2
63
RoW
GP combine with Tislelizumab neoadjuvant therapy+CCRT
Sun Yat-sen University
Nasopharyngeal Carcinoma
11/25
11/26
YKP2023-02-04, NCT06445088: Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma

Recruiting
N/A
908
RoW
VCA-IgA, EBNA1-IgA, and EBV-DNA, EBV C Promoter Methylation Detection in nasopharyngeal swab samples
Sun Yat-sen University, Fujian Cancer Hospital, Wuzhou Red Cross Hospital, Zhongshan People's Hospital, Guangdong, China, First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
12/26
12/26
Mai, Hai
NCT05304468: Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Active, not recruiting
3
452
RoW
IMRT, induction chemotherapy, cisplatin concurrent chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
10/26
10/29
NCT03668730: Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma

Active, not recruiting
2
215
RoW
Intensity-modulated radiation therapy, Paclitaxel liposome, Cisplatin, 5-Fluorouracil
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/21
12/23
CANPCSS, NCT03637634: The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study

Not yet recruiting
N/A
1000
NA
Hai-Qiang Mai,MD,PhD, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital of Jinan University, Nanfang Hospital of Southern Medical University, Affiliated Cancer Hospital of Shantou University Medical College, Zhanjiang Cancer Hospital, Affiliated Zhongshan Hospital, Sun Yat-Sen University, First People's Hospital of Foshan, Dongguan People's Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University, Shenzhen Second People's Hospital, Jiangmen Central Hospital, Yuebei People's Hospital, Hunan Cancer Hospital, Cancer Hospital of Guizhou Province, Fudan University, Fujian Cancer Hospital, Wuhan Union Hospital, China, The First Affiliated Hospital of Zhengzhou University, Zhejiang Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Shandong Cancer Hospital and Institute, Jiangsu Cancer Institute & Hospital, Jiangxi Provincial Cancer Hospital, Second Affiliated Hospital of Nanchang University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University Cancer Hospital & Institute, Cancer Hospital of Guangxi Medical University, Tongji Hospital
NPC Patients
12/30
12/35
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mai, Hai-qiang
NCT03321539: Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

Active, not recruiting
3
216
RoW
CCRT+GP, Adjuvant GP, CCRT+PF, Adjuvant PF
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/22
12/25
NCT04456322: Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Recruiting
3
326
RoW
RT plus Nimotuzumab, RT plus Cisplatin, Cisplatin
Sun Yat-sen University
Nasopharyngeal Carcinoma
06/23
06/25
NCT03306121: TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma

Active, not recruiting
3
322
RoW
TPF+CCRT, TPF induction chemotherapy, CCRT+ PF, Adjuvant PF
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/23
12/26
NCT05304468: Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Active, not recruiting
3
452
RoW
IMRT, induction chemotherapy, cisplatin concurrent chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
10/26
10/29
NCT06712888: Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Recruiting
3
466
RoW
TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy, GP plus placebo induction therapy
Sun Yat-sen University, First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University Cancer Center, Affiliated Hospital of Guangdong Medical University, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, The University of Hong Kong-Shenzhen Hospital, Hunan Cancer Hospital, The Affiliated Cancer Hosipital of Guizhou Meidical University, Sichuan Cancer Hospital and Research Institute, Fujian Cancer Hospital
Nasopharyngeal Carcinoma (NPC)
01/30
01/32
NCT05979961: Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Recruiting
3
454
RoW
IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy)
Sun Yat-sen University, First Affiliated Hospital of Guangxi Medical University, Zhongshan People's Hospital, Guangdong, China, Wuhan Union Hospital, China, Tongji Hospital, Guangzhou Panyu Central Hospital, Hunan Cancer Hospital, Cancer Hospital of Guizhou Province
Nasopharyngeal Carcinoma
09/26
09/29
NCT03925090: Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Active, not recruiting
2
150
RoW
Cisplatin+Toripalimab, DDP+ JS001, Cisplatin+placebo, DDP
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/21
10/23
NCT05193617: Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Active, not recruiting
2
104
RoW
GP+Penpulimab+Anlotinib, GP+AK105+AL3818, GP+Penpulimab, GP+AK105
Sun Yat-sen University
Nasopharyngeal Carcinoma
01/25
01/27
NCT06301165: TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma

Recruiting
2
162
RoW
TPC induction chemotherapy, GP induction chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/24
12/28
NCT04833257: Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC

Recruiting
2
63
RoW
GP combine with Tislelizumab neoadjuvant therapy+CCRT
Sun Yat-sen University
Nasopharyngeal Carcinoma
11/25
11/26
YKP2023-02-04, NCT06445088: Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma

Recruiting
N/A
908
RoW
VCA-IgA, EBNA1-IgA, and EBV-DNA, EBV C Promoter Methylation Detection in nasopharyngeal swab samples
Sun Yat-sen University, Fujian Cancer Hospital, Wuzhou Red Cross Hospital, Zhongshan People's Hospital, Guangdong, China, First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
12/26
12/26
Mai, Hai
NCT05304468: Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Active, not recruiting
3
452
RoW
IMRT, induction chemotherapy, cisplatin concurrent chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
10/26
10/29
NCT03668730: Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma

Active, not recruiting
2
215
RoW
Intensity-modulated radiation therapy, Paclitaxel liposome, Cisplatin, 5-Fluorouracil
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/21
12/23
CANPCSS, NCT03637634: The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study

Not yet recruiting
N/A
1000
NA
Hai-Qiang Mai,MD,PhD, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital of Jinan University, Nanfang Hospital of Southern Medical University, Affiliated Cancer Hospital of Shantou University Medical College, Zhanjiang Cancer Hospital, Affiliated Zhongshan Hospital, Sun Yat-Sen University, First People's Hospital of Foshan, Dongguan People's Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University, Shenzhen Second People's Hospital, Jiangmen Central Hospital, Yuebei People's Hospital, Hunan Cancer Hospital, Cancer Hospital of Guizhou Province, Fudan University, Fujian Cancer Hospital, Wuhan Union Hospital, China, The First Affiliated Hospital of Zhengzhou University, Zhejiang Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Shandong Cancer Hospital and Institute, Jiangsu Cancer Institute & Hospital, Jiangxi Provincial Cancer Hospital, Second Affiliated Hospital of Nanchang University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University Cancer Hospital & Institute, Cancer Hospital of Guangxi Medical University, Tongji Hospital
NPC Patients
12/30
12/35

Download Options